-
Risk Factors for Hyperosmolar Hyperglycemic State in Pediatric Type 2 Diabetes. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-06-09 Estelle M Everett,Timothy Copeland,Lauren E Wisk,Lily C Chao
Background There is a paucity of data on the risk factors for the hyperosmolar hyperglycemic state (HHS) compared with diabetic ketoacidosis (DKA) in pediatric type 2 diabetes (T2D). Methods We used the national Kids' Inpatient Database to identify pediatric admissions for DKA and HHS among those with T2D in the years 2006, 2009, 2012, and 2019. Admissions were identified using ICD codes. Those aged
-
Situational Awareness and Proactive Engagement Predict Higher Time in Range in Adolescents and Young Adults Using Hybrid Closed-Loop. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-05-18 Laurel H Messer,Paul F Cook,Stephen Voida,Casey Fiesler,Emily Fivekiller,Chinmay Agrawal,Tian Xu,Gregory P Forlenza,Sriram Sankaranarayanan
Background Adolescents and young adults with type 1 diabetes have high HbA1c levels and often struggle with self-management behaviors and attention to diabetes care. Hybrid closed-loop systems (HCL) like the t:slim X2 with Control-IQ technology (Control-IQ) can help improve glycemic control. The purpose of this study is to assess adolescents' situational awareness of their glucose control and engagement
-
Formative Development of a Weight Management Intervention for Adolescents with Type 1 Diabetes Mellitus and Obesity. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-04-19 Jennifer Warnick,Katherine E Darling,Lisa Swartz Topor,Elissa Jelalian
The prevalence of overweight and obesity in youth with type 1 diabetes mellitus (T1D) now exceeds that of youth without T1D. Comorbid T1D and excess adiposity are associated with multiple serious negative health outcomes. Unfortunately, youth with T1D are often excluded from and/or not referred to standard behavioral lifestyle interventions. This is often attributed to the complexities of managing
-
School-based diabetes care: A national survey of U.S. pediatric diabetes providers. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-04-11 Christine A March,Linda M Siminerio,Traci M Kazmerski,Anastasia Albanese-O'Neill,Elizabeth Miller,Ingrid Libman
Objectives To understand the practices, attitudes, and beliefs of type 1 diabetes (T1D) providers towards school-based diabetes care (SBDC), including counseling families and communicating with schools, and explore the barriers and facilitators which affect their support of SBDC. Research Design and Methods We conducted a national survey of pediatric T1D providers about their perceived support of SBDC
-
Sedentary Behavior and Physical Activity Associated with Psychosocial Outcomes in Adolescents with Type 1 Diabetes. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-04-05 Daniel R Tilden,Amy E Noser,Sarah S Jaser
Background Adolescents with type 1 diabetes (T1D) are particularly vulnerable to poor psychosocial outcomes-high rates of diabetes distress and poor quality of life are common among this cohort. Previous work in the general population demonstrated positive associations between quality of life and increases in moderate-to-vigorous physical activity (MVPA), as well as decreased sedentary behavior. While
-
Comparisons of school-day glycemia in different settings for children with type 1 diabetes using continuous glucose monitoring. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-03-09 Christine A March,Michelle Nanni,James Lutz,Madison Kavanaugh,Kwonho Jeong,Linda M Siminerio,Scott Rothenberger,Elizabeth Miller,Ingrid M Libman
Objective Using continuous glucose monitoring (CGM), we examined patterns in glycemia during school hours for children with type 1 diabetes, exploring differences between school and non-school time. Methods We conducted a retrospective analysis of CGM metrics in children 7-12 years (n=217, diabetes duration 3.5±2.5 years, hemoglobin A1c 7.5±0.8%). Metrics were obtained for weekday school hours (8 AM
-
School Nurse Confidence with Diabetes Devices in Relation to Diabetes Knowledge and Prior Training: A Study of Convergent Validity. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-02-24 Christine A March,Amber Hill,Traci M Kazmerski,Linda Siminerio,Galen Switzer,Elizabeth Miller,Ingrid Libman
Objective The Diabetes Device Confidence Scale (DDCS) is a new scale designed to evaluate school nurse confidence with diabetes devices. We hypothesized that DDCS score would be associated with related constructs of school nurse diabetes knowledge, experience, and training. Research Design and Methods In a cross-sectional study, we co-administered the DDCS and Diabetes Knowledge Test 2 (DKT2) questionnaires
-
Dietary Intake and Body Mass Index Influence the Risk of Islet Autoimmunity in Genetically At-Risk Children: A Mediation Analysis Using the TEDDY Cohort. Pediatr. Diabetes (IF 3.4) Pub Date : 2023-02-17 Carin Andrén Aronsson,Roy Tamura,Kendra Vehik,Ulla Uusitalo,Jimin Yang,Michael J Haller,Jorma Toppari,William Hagopian,Richard A McIndoe,Marian J Rewers,Anette-G Ziegler,Beena Akolkar,Jeffrey P Krischer,Jill M Norris,Suvi M Virtanen,Helena Elding Larsson
Background/Objective Growth and obesity have been associated with increased risk of islet autoimmunity (IA) and progression to type 1 diabetes. We aimed to estimate the effect of energy-yielding macronutrient intake on the development of IA through BMI. Research Design and Methods Genetically at-risk children (n = 5,084) in Finland, Germany, Sweden, and the USA, who were autoantibody negative at 2
-
ISPAD Annual Conference 2022 highlights Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Sze May Ng, Helen Day, Jody B. Grundman, Peerzada Ovais Ahmad, Maja Raicevic, Tinotenda Dzikiti, Nancy Katkat, Anju Jacob, Marisa Ferreira Clemente, Hussain Alsaffar, Yasmine Ibrahim Elhenawy, Yasmine Abdelmeguid, Klemen Dovc
CONFLICT OF INTEREST All the authors declare no other conflict of interests.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Editorial Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Maria E. Craig, Ethel Codner, Farid H. Mahmud, M. Loredana Marcovecchio, Linda A. DiMeglio, Leena Priyambada, Joseph I. Wolfsdorf
The ISPAD 2022 clinical practice consensus guidelines were developed and completed during unprecedented times. First, due to the impact of the COVID-19 pandemic on people with diabetes and their families, diabetes professionals and care teams, our own families, health systems throughout the world, public health policy, and our individual work practices. Second, in the 4 years since the 2018 guidelines
-
ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Ingrid Libman, Aveni Haynes, Sarah Lyons, Praveen Pradeep, Edson Rwagasor, Joanna Yuet-ling Tung, Craig A. Jefferies, Richard A. Oram, Dana Dabelea, Maria E. Craig
CONFLICT OF INTEREST The authors declare no conflict of interest.
-
ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Siri Atma W. Greeley, Michel Polak, Pål R. Njølstad, Fabrizio Barbetti, Rachel Williams, Luis Castano, Klemens Raile, Dung Vu Chi, Abdelhadi Habeb, Andrew T. Hattersley, Ethel Codner
1 WHAT IS NEW OR DIFFERENT Addition of recently described subtypes of monogenic diabetes, including causes associated with diabetes in infancy (CNOT1, ONECUT1, YIPF5, EIF2B1, KCNMA1); and genetic causes associated with diabetes later in life (TRMT10A, DNAJC3, KCNK16, DUT). The expanding list of genes causing monogenic diabetes further emphasizes comprehensive next-generation sequencing (NGS) as the
-
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Katie Larson Ode, Manfred Ballman, Alberto Battezzati, Amanda Brennan, Christine L. Chan, Shihab Hameed, Heba M. Ismail, Andrea Kelly, Antoinette M. Moran, Remi Rabasa-Lhoret, Nichole A. Saxby, Maria E. Craig
1 WHAT IS NEW OR DIFFERENT? For some people with cystic fibrosis (CF), a new and life-changing era has begun; however, for others, existing disparities have only increased. The lives of persons with CF (PwCF) have been profoundly changed by the advent of highly effective CF transmembrane conductance regulator (CFTR) modulator therapy (HEMT) (elexacaftor/tezacaftor/ivacaftor combination therapy or ivacaftor
-
ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Martin de Bock, Ethel Codner, Maria E. Craig, Tony Huynh, David M. Maahs, Farid H. Mahmud, Loredana Marcovecchio, Linda A. DiMeglio
1 WHAT IS NEW OR DIFFERENT Inclusion of continuous glucose monitoring (CGM) targets for children, adolescents, and young adults <25 years. Emphasis on individualized care plans that make use of effective educational strategies to achieve glucose targets that are person-centered and designed to empower young people and caregivers. These plans should incorporate cognitive behavioral techniques that encompass:
-
ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Eda Cengiz, Thomas Danne, Tariq Ahmad, Ahila Ayyavoo, David Beran, Sarah Ehtisham, Jan Fairchild, Przemyslawa Jarosz-Chobot, Sze May Ng, Megan Paterson, Ethel Codner
CONFLICT OF INTEREST E. Cengiz is a scientific advisor for Eli Lilly, Novo Nordisk, Adocia and Arecor. TD has received speaker's honoraria and research support from or has consulted for Astra Zeneca, Bayer, Boehringer, Dexcom, Eli Lilly, Lifescan, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, Ypsomed and is a shareholder of Drea Med Ltd. TA, JF, DB, SH, MP, E. Codner have no disclosures.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Mary B. Abraham, Beate Karges, Klemen Dovc, Diana Naranjo, Ana Maria Arbelaez, Joyce Mbogo, Ganesh Javelikar, Timothy W. Jones, Farid H. Mahmud
1 WHAT IS NEW OR DIFFERENT? Updated recommendations of maximum permissible time in hypoglycemia, as defined by continuous glucose monitoring (CGM) metrics as well as details for treatment of hypoglycemia. Added descriptions of newer easy-to-use formulations of glucagon approved for use, which have variable availability across different regions of the world. Updated details from studies of newer insulin
-
ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Peter Adolfsson, Craig E. Taplin, Dessi P. Zaharieva, John Pemberton, Elizabeth A. Davis, Michael C. Riddell, Jonathan McGavock, Othmar Moser, Agnieszka Szadkowska, Prudence Lopez, Jeerunda Santiprabhob, Elena Frattolin, Gavin Griffiths, Linda A. DiMeglio
1 WHAT IS NEW OR DIFFERENT Since the previous guideline, progress has been made in the field of diabetes management and physical activity (PA).1 An e-book that includes 10 articles on PA and type 1 diabetes (T1D) has been published2 and the epidemiological evidence and gaps in knowledge and research in this book have been recently reviewed (Section 7).3 Impact of age, sex, and physical fitness glucose
-
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Martin Tauschmann, Gregory Forlenza, Korey Hood, Roque Cardona-Hernandez, Elisa Giani, Christel Hendrieckx, Daniel J. DeSalvo, Lori M. Laffel, Banshi Saboo, Benjamin J. Wheeler, Dmitry N. Latpev, Iroro Yarhere, Linda A. DiMeglio
SUMMARY OF WHAT IS NEW OR DIFFERENT Since publication of the 2018 guidelines, the area of glucose monitoring has evolved, especially as regards continuous glucose monitoring (CGM) systems. CGM is more widely available in many parts of the world; latest generation devices are factory-calibrated, more accurate, and do not need a confirmatory fingerstick blood glucose measurement. More studies regarding
-
ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Petter Bjornstad, Allison Dart, Kim C. Donaghue, Axel Dost, Eva L. Feldman, Gavin S. Tan, R. Paul Wadwa, Bedowra Zabeen, M. Loredana Marcovecchio
CONFLICT OF INTEREST PB has acted as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Sanofi, Novo Nordisk and Horizon Pharma. PB serves on the advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. RPW has research support from Dexcom, Eli Lilly & Co and Tandem Diabetes Care. RPW has served on an advisory board for Dompe.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Other complications and associated conditions in children and adolescents with type 1 diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Elke Fröhlich-Reiterer, Nancy S. Elbarbary, Kimber Simmons, Bruce Buckingham, Khadija N. Humayun, Jesper Johannsen, Reinhard W. Holl, Shana Betz, Farid H. Mahmud
CONFLICT OF INTEREST The authors have declared no relevant conflicts of interest.
-
ISPAD clinical practice consensus guidelines 2022: Management of children and adolescents with diabetes requiring surgery Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Thomas Kapellen, Juliana Chizo Agwu, Lizabeth Martin, Seema Kumar, Marianna Rachmiel, Declan Cody, Sunkara V. S. G. Nirmala, M. Loredana Marcovecchio
CONFLICT OF INTEREST The authors have declared no relevant conflicts of interest.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Management and support of children and adolescents with diabetes in school Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Sarah E. Lawrence, Anastasia Albanese-O'Neill, Stéphane Besançon, Taryn Black, Nataša Bratina, David Chaney, Fran R. Cogen, Elizabeth A. Cummings, Elizabeth Moreau, Jessica S. Pierce, Erick Richmond, Farid H. Mahmud
CONFLICT OF INTEREST The authors declare that there is no conflict of interest.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Frida Sundberg, Carine deBeaufort, Lars Krogvold, Susana Patton, Thereza Piloya, Carmel Smart, Michelle Van Name, Jill Weissberg-Benchell, Jose Silva, Linda A. diMeglio
1 SUMMARY OF WHAT IS NEW OR DIFFERENT Preschool children with type 1 diabetes (T1D) who have access to modern diabetes care can safely achieve a HbA1c below 48 mmol/mol (6.5%). Continuous glucose monitoring (CGM) is the recommended tool for glycemic monitoring in preschoolers with T1D. When using CGM, a reasonable treatment target is 50% time in target (TIT) 3.9–7.8 mmol/L (70–140 mg/dL) or 70% time
-
ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Asma Deeb, Amir Babiker, Sara Sedaghat, Ahmed El Awwa, Kowshik Gupta, Aman Bhakti Pulungan, Umar Isa Umar, Zhanay Akanov, Sanjay Kalra, David Zangen, Sara Al Adhami, Melina Karipidou, M. Loredana Marcovecchio
1 WHAT IS NEW OR DIFFERENT The 2022 edition of the guideline provides updates of previous sections and includes fasting in other religions in addition to Ramadan. Evidence on the use of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) during fasting. Fasting in young people with type 2 diabetes (T2D).
-
ISPAD Clinical Practice Consensus Guidelines 2022: Management of the child, adolescent, and young adult with diabetes in limited resource settings Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-20 Anju Virmani, Stuart J. Brink, Angela Middlehurst, Fauzia Mohsin, Franco Giraudo, Archana Sarda, Sana Ajmal, Julia E. von Oettingen, Kuben Pillay, Supawadee Likitmaskul, Luis Eduardo Calliari, Maria E. Craig
CONFLICT OF INTEREST Anju Virmani, Stuart J. Brink, Angela Middlehurst, Fauzia Mohsin, Franco Giraudo, Archana Sarda, Julia E. von Oettingen, Supawadee Likitmaskul, Luis Eduardo Calliari, Maria E Craig: none. Kuben Pillay has received speaker's honoraria from Abbott, Eli Lilly, Novo Nordisk and Sanofi in the last 3 years. Sana Ajmal receives support from Meethi Zindagi which is supported by Eli Lilly
-
ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-05 S. Francesca Annan, Laurie A. Higgins, Elisabeth Jelleryd, Tamara Hannon, Shelley Rose, Sheryl Salis, Juliana Baptista, Paula Chinchilla, Maria Loredana Marcovecchio
CONFLICT OF INTEREST The author declares that there is no conflict of interest.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-05 Jennifer L. Sherr, Melissa Schoelwer, Tiago Jeronimo Dos Santos, Leenatha Reddy, Torben Biester, Alfonso Galderisi, Jacobus Cornelius van Dyk, Marisa E. Hilliard, Cari Berget, Linda A. DiMeglio
CONFLICT OF INTEREST J.L.S. reports having received speaker honoraria from Eli Lilly, Insulet, Medtronic, and Zealand and serves on advisory boards of Bigfoot Biomedical, Cecelia Health, Insulet Corporation, Medtronic Diabetes, JDRF T1D Fund, and Vertex. She has been a consultant for Insulet and Medtronic. J.L.S.'s institution received research grant support from JDRF, Medtronic, Insulet, and NIDDK
-
ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-12-05 Maartje de Wit, Katarzyna A. Gajewska, Eveline R. Goethals, Vincent McDarby, Xiaolei Zhao, Given Hapunda, Alan M. Delamater, Linda A. DiMeglio
1 WHAT IS NEW OR DIFFERENT Psychological care of youth with type 1 diabetes (T1D) as well as type 2 diabetes (T2D) is covered. Additional sections on the psychological assessment, communication, the health care team and psychological impact of technology are added
-
Clinical characteristics and cardiovascular risk profile in children and adolescents with latent autoimmune diabetes: Results from the German/Austrian prospective diabetes follow-up registry Pediatr. Diabetes (IF 3.4) Pub Date : 2022-11-05 Alena Welters, Sascha R. Tittel, Thomas Reinehr, Daniel Weghuber, Susanna Wiegand, Wolfram Karges, Clemens Freiberg, Thomas Meissner, Nanette C. Schloot, Reinhard W. Holl
To characterize children and adolescents with latent autoimmune diabetes of the young (LADY), and to assess the utility of classifying individuals as LADYs regarding their cardiovascular (CV) risk factors.
-
The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-study Pediatr. Diabetes (IF 3.4) Pub Date : 2022-11-02 Janne Houben, Martha Janssens, Christiane Winkler, Rachel Elizabeth Jane Besser, Katarzyna Dzygalo, Annika Fehn, Angela Hommel, Karin Lange, Helena Elding Larsson, Markus Lundgren, Frank Roloff, Matthew Snape, Agnieszka Szypowska, Andreas Weiss, Jose Zapardiel-Gonzalo, Nicole Zubizarreta, Anette-Gabriele Ziegler, Kristina Casteels
This study examined the emotional impact that parents experience when confronted with an increased genetic risk of type 1 diabetes (T1D) in their child. Population-based screening of neonates for genetic risk of chronic disease carries the risk of increased emotional burden for parents.
-
Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-11-01 Barbara Piccini, Benedetta Pessina, Emilio Casalini, Lorenzo Lenzi, Sonia Toni
Advanced hybrid closed loop (AHCL) systems are the newest tool to improve metabolic control in type 1 diabetes (T1D). Long-term glycemic control of children and adolescents with T1D switching to MiniMed™ 780G in a real clinical setting was evaluated.
-
Quality improvement efforts in a safety net institution: Increased diabetes screening is associated with lower HbA1c at diagnosis and improved HbA1c outcomes in youth with type 2 diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-27 Kathy Love-Osborne, Haley Ringwood, Jeanelle Sheeder, Phil Zeitler
Evaluate whether increased diabetes screening in youth is associated with lower HbA1c at T2D diagnosis and improved HbA1c outcomes in youth.
-
Insulin delivery patterns required to maintain postprandial euglycemia in type 1 diabetes following consumption of traditional Egyptian Ramadan Iftar meal using insulin pump therapy: A randomized crossover trial Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-26 Nancy Samir Elbarbary, Yasmine Ibrahim Elhenawy, Ali Rezq Reyd Ali, Carmel E. Smart
During Ramadan, traditional Egyptian Iftar meals have large amounts of high-glycemic index carbohydrate and fat. The efficacy of different bolus regimens on optimizing post prandial glucose (PPG) excursion following this Iftar meal was assessed.
-
Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-20 Elise Schlissel Tremblay, Kate Millington, Yunhong Wu, David Wypij, Yufan Yang, Michael S. D. Agus, Joseph Wolfsdorf
Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.
-
Efficacy of insulin dosing algorithms for high-fat high-protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: A systematic review and meta-analysis Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-19 Rana Al Balwi, Wedad Al Madani, Amal Al Ghamdi
Optimizing postprandial blood glucose (PPG) levels after mixed meals that contain high fat and protein remains a challenge in the treatment of type 1 diabetes. This study evaluated the efficacy of different algorithms used for dosing insulin based on counting units of high fat and high protein (HFHP) meals with the current conventional method of counting carbohydrates alone to control PPG excursions
-
ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-17 Nicole Glaser, Maria Fritsch, Leena Priyambada, Arleta Rewers, Valentino Cherubini, Sylvia Estrada, Joseph I. Wolfsdorf, Ethel Codner
CONFLICT OF INTEREST None of the authors has any conflicts of interest relevant to the subject matter of the article.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes in adolescence Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-17 John W. Gregory, Fergus J. Cameron, Kriti Joshi, Mirjam Eiswirth, Christopher Garrett, Katharine Garvey, Shivani Agarwal, Ethel Codner
1 SUMMARY OF WHAT IS NEW/DIFFERENT Modern insulin therapy produces normal or minimally delayed puberty. Despite recent technological advances in the care of diabetes, achieving optimal glycemic control during adolescence remains challenging. Peer support through online social media is an increasingly important source of advice. Motivational interviewing by psychologists is effective in optimizing outcomes
-
Proceedings of 21st ISPAD science school for physicians 2022 Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-17 Tiago Jeronimo dos Santos, Agata Chobot, Claudia Piona, Klemen Dovc, Torben Biester, Katarzyna Anna Gajewska, Carine de Beaufort, Zdenek Sumnik, Lenka Petruzelkova
CONFLICT OF INTEREST The authors declare no conflicts of interest.
-
Association of psychosocial factors with medication adherence in emerging adults with youth-onset type 2 diabetes: The iCount study Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-11 Paula M. Trief, Seth Kalichman, Diane Uschner, Melinda Tung, Kimberly L. Drews, Barbara J. Anderson, Lida M. Fette, Hui Wen, Jane D. Bulger, Ruth S. Weinstock
To assess associations of psychosocial factors with medication adherence in young adults with youth-onset type 2 diabetes in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY2) cohort.
-
Effects of interrupting daily sedentary behavior on children's glucose metabolism: A 6-day randomized controlled trial Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-07 Miranda M. Broadney, Britni R. Belcher, Nejla Ghane, Risha Sheni, Michael J. Jayson, Robert W. Trenschel, Shavonne M. Collins, Robert J. Brychta, Elisabeth K. Davis, Sheila M. Brady, Shanna B. Yang, Amber B. Courville, Kevin P. Smith, Douglas R. Rosing, Kong Y. Chen, Jack A. Yanovski
Metabolic disease risk in youth is influenced by sedentary behaviors. Acute in-lab studies show that, during a single day, interrupting a sedentary period with short bouts of physical activity improves glucometabolic outcomes.
-
Survival of children and youth with type 1 diabetes mellitus in Tanzania Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-04 Edna Siima Majaliwa, Linda Minja, Joel Ndayongeje, Kaushik Ramaiya, Sayoki G. Mfinanga, Blandina T. Mmbaga
Survival from type 1 diabetes Mellitus is low in lower-income countries with underdeveloped health systems. Support programs from partners like life for a child (LFAC) and changing diabetes in children (CDiC) were implemented in Tanzania in 2005 to provide diabetes care to children and youth. No evaluation of survival has been done since their implementation.
-
-
Insulin resistance relates to DKA severity and affects insulin requirement in children with type 1 diabetes at onset Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-01 Concetta Mastromauro, Nella Polidori, Annalisa Blasetti, Laura Comegna, Francesco Chiarelli, Angelika Mohn, Cosimo Giannini
Fluid and insulin treatments are the cornerstones of DKA management and indications on dosages are available. However, according to possible confounding factors, relevant data are still required to explain the different insulin dosages adopted at diabetes onset, particularly based upon insulin sensitivity.
-
Adolescent ambivalence about diabetes technology—The Janus faces of automated care Pediatr. Diabetes (IF 3.4) Pub Date : 2022-10-01 Fergus J. Cameron, Michael Arnold, John W. Gregory
The Janus face metaphor approach highlights that a technology may simultaneously have two opposite faces or properties with unforeseen paradoxes within human-technology interaction. Suboptimal acceptance and clinical outcomes are sometimes seen in adolescents who use diabetes-related technologies. A traditional linear techno-determinist model of technology use would ascribe these unintended outcomes
-
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-30 Rachel E. J. Besser, Kirstine J. Bell, Jenny J. Couper, Anette-G. Ziegler, Diane K. Wherrett, Mikael Knip, Cate Speake, Kristina Casteels, Kimberly A. Driscoll, Laura Jacobsen, Maria E. Craig, Michael J. Haller
CONFLICT OF INTEREST The authors have declared no conflicts of interest.
-
Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-29 John M. Wentworth, Helena Oakey, Maria E. Craig, Jennifer J. Couper, Fergus J. Cameron, Elizabeth A. Davis, Antony R. Lafferty, Mark Harris, Benjamin J. Wheeler, Craig Jefferies, Peter G. Colman, Leonard C. Harrison
Islet autoantibody screening of infants and young children in the Northern Hemisphere, together with semi-annual metabolic monitoring, is associated with a lower risk of ketoacidosis (DKA) and improved glucose control after diagnosis of clinical (stage 3) type 1 diabetes (T1D). We aimed to determine if similar benefits applied to older Australians and New Zealanders monitored less rigorously.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-25 Amy S. Shah, Philip S. Zeitler, Jencia Wong, Alexia S. Pena, Brandy Wicklow, Silva Arslanian, Nancy Chang, Junfen Fu, Preeti Dabadghao, Orit Pinhas-Hamiel, Tatsuhiko Urakami, Maria E. Craig
Since the 2018 ISPAD guidelines on this topic, follow-up of large cohorts from around the globe have continued informing the current incidence and prevalence of co-morbidities and complications in young adults with youth-onset type 2 diabetes (T2D). This chapter focuses on the risk factors, diagnosis and presentation of youth-onset T2D, the initial and subsequent management of youth-onset T2D, and
-
Corneal nerve and nerve conduction abnormalities in children with type 1 diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-21 Danièle Pacaud, Kenneth G. Romanchuk, Heidi Virtanen, Maryam Ferdousi, Alberto Nettel-Aguirre, Jean K. Mah, Mitra Tavakoli, Douglas W. Zochodne, Rayaz A. Malik
In vivo corneal confocal microscopy (CCM) is a novel, rapid, and non-invasive technique that identifies early small fiber damage and can predict the progression and development of clinical neuropathy in adults with type 1 diabetes. However, its usefulness in children is not well established. This study compared corneal confocal microscopy with neuropathic symptoms, signs, and objective measures of
-
Impact of dysglycemia and obesity on the brain in adolescents with and without type 2 diabetes: A pilot study Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-21 Lydia L. Snyder, Lara C. Foland-Ross, Allison Cato, Allan L. Reiss, Chetan Shah, Jobayer Hossain, Hussein Elmufti, Nelly Mauras
Both diabetes and obesity can affect the brain, yet their impact is not well characterized in children with type 2 (T2) diabetes and obesity. This pilot study aims to explore differences in brain function and cognition in adolescents with T2 diabetes and obesity and nondiabetic controls with obesity and lean controls.
-
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes education in children and adolescents Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-19 Anna Lindholm Olinder, Matthew DeAbreu, Stephen Greene, Anne Haugstvedt, Karin Lange, Edna S. Majaliwa, Vanita Pais, Julie Pelicand, Marissa Town, Farid H. Mahmud
1 SUMMARY OF WHAT IS NEW OR DIFFERENT This chapter has been updated with additional details and references on educational approaches for multidisciplinary teams, including cultural adaptation, as well as a section on type 2 diabetes (T2D) in youth. Diabetes education and digital technologies as well as telemedicine, with increased adoption of video or phone appointments, has also been expanded and
-
Differences in retinopathy prevalence and associated risk factors across 11 countries in three continents: A cross-sectional study of 156,090 children and adolescents with type 1 diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-13 Natasa Bratina, Marie Auzanneau, Niels Birkebæk, Carine de Beaufort, Valentino Cherubini, Maria E. Craig, Dana Dabelea, Klemen Dovc, Sabine E. Hofer, Reinhard W. Holl, Elizabeth T. Jensen, Dick Mul, Katrin Nagl, Holly Robinson, Ulrike Schierloh, Jannet Svensson, Valentina Tiberi, Henk J. Veeze, Justin T. Warner, Kim C. Donaghue
To examine the prevalence, time trends, and risk factors of diabetic retinopathy (DR) among youth with type 1 diabetes (T1D) from 11 countries (Australia, Austria, Denmark, England, Germany, Italy, Luxemburg, Netherlands, Slovenia, United States, and Wales).
-
Sick day management in children and adolescents with diabetes Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-12 Helen Phelan, Ragnar Hanas, Sabine E. Hofer, Steven James, Alanna Landry, Warren Lee, Jamie R. Wood, Ethel Codner
CONFLICT OF INTEREST Jamie R. Wood has research grants unrelated to the current manuscript from the following: AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and MannKind. Sabine E. Hofer has received lecturing honoraria from Eli Lilly, Sanofi, Medtronic, Pfizer, Insulet and Vertex. Ragnar Hanas has consulting activities unrelated to the current manuscript with Abbott, AstraZeneca and NovoNordisk
-
Type 1 diabetes knowledge assessment: The KAT-1 validation study Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-11 Anastasia Albanese-O'Neill, Jann MacInnes, Michael J. Haller, Janey Adams, Nicole Thomas, Angelina Bernier
This study sought to examine the reliability and validity of a novel pediatric type 1 diabetes knowledge assessment (KAT-1) designed for children, adolescents, young adults and their parents/guardians. The instrument was designed to be integrated into the clinic workflow to obtain objective data electronically.
-
HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-09 Falastin Salami, Roy Tamura, Lu You, Åke Lernmark, Helena Elding Larsson, Markus Lundgren, Jeffrey Krischer, Anette-Gabriele Ziegler, Jorma Toppari, Riitta Veijola, Marian Rewers, Michael J. Haller, William Hagopian, Beena Akolkar, Carina Törn
Increased level of glycated hemoglobin (HbA1c) is associated with type 1 diabetes onset that in turn is preceded by one to several autoantibodies against the pancreatic islet beta cell autoantigens; insulin (IA), glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8). The risk for type 1 diabetes diagnosis increases by autoantibody number. Biomarkers predicting the
-
Clinical features, biochemistry, and HLA-DRB1 status in youth-onset type 1 diabetes in Mali Pediatr. Diabetes (IF 3.4) Pub Date : 2022-09-05 Stéphane Besançon, Denira Govender, Assa Traore Sidibé, Janelle Annette Noble, Amagara Togo, Julie Ann Lane, Steven John Mack, Mark A. Atkinson, Clive Henry Wasserfall, Faizy Kakkat, Gregory G. N. Martin, Graham David Ogle
Limited information is available regarding youth-onset diabetes in Mali. We investigated demographic, clinical, biochemical, and genetic features in new diabetes cases in children and adolescents.
-
A pragmatic low carbohydrate diet intervention changes neither carbohydrate consumption nor glycemia in adolescents and young adults with type 1 diabetes in a randomized trial Pediatr. Diabetes (IF 3.4) Pub Date : 2022-08-24 Sara H. Duffus, James C. Slaughter, William Cooley, Navila Sharif, Kimberly Rainer, Katie C. Coate, Sarah S. Jaser, Daniel J. Moore, Kevin D. Niswender, Justin M. Gregory
Despite enthusiasm for low carbohydrate diets (LCDs) among patients with type 1 diabetes (T1DM), no prospective study has investigated outcomes in adolescent T1DM. We aimed to quantify a pragmatic LCD intervention's impact on glycemia, lipidemia, and quality of life (QOL) in adolescents with T1DM.
-
Corrigendum Pediatr. Diabetes (IF 3.4) Pub Date : 2022-08-19
In the article de Gouveia Buff Passone et al.,1 the authors would like to acknowledge that this work was financed in part by a grant from the Agence Nationale de la Recherche (ANR) called Neurogli.
-
Type 1 diabetes incidence increased during the COVID-19 pandemic years 2020–2021 in Czechia: Results from a large population-based pediatric register Pediatr. Diabetes (IF 3.4) Pub Date : 2022-08-18 Ondřej Cinek, Matvei Slavenko, Renata Pomahačová, Petra Venháčová, Lenka Petruželková, Jaroslav Škvor, David Neumann, Jan Vosáhlo, Petra Konečná, Kamila Kocourková, Jiří Strnadel, Štěpánka Průhová, Zdeněk Šumník
To explore type 1 diabetes incidence patterns during the pandemic years 2020 and 2021 in Czechia, to compare them to the trends from the previous decade, and to test its association with indicators of containment measures and of pandemic severity (school closing and the all-cause excess mortality).
-
A longitudinal assessment of diabetes autoantibodies in the SEARCH for diabetes in youth study Pediatr. Diabetes (IF 3.4) Pub Date : 2022-08-17 Lina Merjaneh, Lawrence M. Dolan, Cynthia K. Suerken, Ralph D'Agostino, Giuseppina Imperatore, Sharon Saydah, Alissa Roberts, Santica Marcovina, Elizabeth J. Mayer-Davis, Dana Dabelea, Jean M. Lawrence, Catherine Pihoker
To assess changes in diabetes autoantibodies (DAs) over time in children and young adults with diabetes and determine whether observed changes were associated with demographic characteristics, clinical parameters and diabetes complications. Participants had DAs measured at baseline (10.3 ± 7.1 months after diabetes diagnosis) and at 12, 24 months and ≥5 years after the baseline measurement. At the
-
Pancreatic beta-cell function dynamics in youth with GCK, HNF1A, and KCNJ11 genes mutations during mixed meal tolerance test Pediatr. Diabetes (IF 3.4) Pub Date : 2022-08-17 Ingrida Stankute, Rimante Dobrovolskiene, Evalda Danyte, Rasa Steponaviciute, Valerie M. Schwitzgebel, Rasa Verkauskiene
The aims were (1) to assess beta-cell function in GCK diabetes patients over 2-year period; (2) to evaluate the dynamics of beta-cell function in HNF1A and KCNJ11 patients after treatment optimization; using mixed meal tolerance test (MMTT) as a gold standard for non-invasive beta-cell function assessment.